Maze Therapeutics, Inc. 4

Sophie Kornowski was granted stock options for 36,000 shares of Maze Therapeutics, Inc. common stock at an exercise price of $27.665 on August 13, 2026.

On August 13, 2026, reporting person Sophie Kornowski received a stock option grant from Maze Therapeutics, Inc. for 36,000 shares of common stock at an exercise price of $27.665 per share. This award is structured to vest in equal monthly installments of 1/36th of the total grant, beginning on September 13, 2026, with subsequent tranches vesting on each monthly anniversary, contingent on her continued service to the company. Following this grant, her derivative ownership position increased by 36,000 option shares, corresponding to the right to acquire 36,000 shares of Maze common stock, with an aggregate option notional value of approximately $996,000 based on the exercise price.

Filing Facts

CIK

1842295

Ticker

MAZE

Form

4

Source Type

fda

Accession

0001894117-26-000006

Alert Tier

5